Acelrx pharmaceuticals announces peer-reviewed publication on the use of dsuvia® for in-office rhinology procedures

Study is the first to report on the use of dsuvia® in the rapidly growing field of rhinology where otolaryngologists are performing painful nasal and sinus procedures in the office which were historically conducted only in ambulatory surgery centers or hospitals hayward, calif. , march 1, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil sublingual tablet 30 mcg (sst; dsuvia) in otolaryngology case reports.
ACRX Ratings Summary
ACRX Quant Ranking